The Nasonex 24HR Allergy Spray from Perrigo - generic relief with prescription strength

By Daniel Foster, ad hoc news Accessories & Components Desk. Reviewed July 01, 2026, 1:42 AM ET. Details in the imprint.

Nasonex 24HR Allergy Spray sits eye-level on the pharmacy shelf, a matte white bottle with a soft blue band and a slightly rubbery nozzle that feels cool against your thumb as you prime it for a first spray. Designed as Perrigo Company PLC’s generic equivalent to prescription Nasonex, it delivers mometasone furoate in a once-daily nasal corticosteroid for seasonal and perennial allergy relief in the US market. The fine mist has almost no scent, a detail allergy sufferers notice immediately.

Once-daily steroid nasal spray

Nasonex 24HR Allergy Spray contains mometasone furoate 50 mcg per spray, classified as a synthetic corticosteroid indicated for symptoms such as nasal congestion, sneezing, and runny nose associated with allergic rhinitis. The product is marketed as providing 24-hour relief with once-daily dosing for adults and children aged 12 and older, matching the dosing profile long associated with the branded Nasonex prescription nasal spray.

Perrigo describes the generic mometasone furoate nasal spray as bioequivalent to the reference listed drug, meaning it delivers the same active ingredient at the same strength and route of administration, with comparable systemic exposure and local action in the nasal mucosa. In practice, that means the clear, slightly viscous liquid coating the nasal passages with each spray is expected to reach a similar concentration and onset profile as the branded product.

Generic strategy in allergy aisles

On Perrigo’s official product information pages, the company positions Nasonex 24HR Allergy Spray within its US store-brand and private label strategy, highlighting its role as an affordable alternative to branded intranasal steroids. The label calls out mometasone furoate as the active ingredient, and Perrigo emphasizes that the spray is intended to treat both indoor and outdoor allergies, including common triggers such as dust mites, pet dander, and pollens.

In a 2023 discussion of the company’s allergy portfolio, Perrigo CEO Murray Kessler singled out store-brand equivalents to well-known allergy therapies as key contributors to the consumer self-care segment, pointing to nasal sprays and oral antihistamines as examples. Nasonex 24HR Allergy Spray, sold through major US retailers under Perrigo’s label or store brands, fits comfortably into that narrative by bringing a prescription molecule into an accessible OTC format.

US availability and price point

In US pharmacies, Nasonex 24HR Allergy Spray generally appears as an over-the-counter boxed unit containing a single bottle, with the front panel highlighting “24HR” and “allergy” in bold letters alongside the mometasone furoate dose. Retail listings in national chains typically show the spray at prices in the range of 15 to 25 USD for a multi-week supply, depending on store-brand positioning and promotions. That places Perrigo’s product below many branded intranasal steroids, aligning with the company’s focus on value-oriented self-care.

From a consumer perspective, the economics connect directly with usage patterns. A bottle delivering 120 metered sprays, at two sprays per nostril once daily, covers about a month of therapy for a typical adult regimen. Because allergic rhinitis often persists across an entire season, repeat purchases matter, making price sensitivity and generic options especially visible in the allergy aisle. Pharmacists interviewed in trade coverage note that patients often start with a branded nasal spray and switch to a generic equivalent once they see that the feel, scent, and symptom relief are comparable.

How the spray feels and works in use

The physical experience of Nasonex 24HR Allergy Spray begins with the priming step. With the cap removed, you typically hold the bottle between your thumb and two fingers, then pump until a fine, soft mist appears from the nozzle, a standard requirement to ensure dosing accuracy with metered sprays. When inserted into the nostril and activated, the spray produces a brief, cool sensation, followed by a neutral aftertaste due to the formulation’s low perfume and flavor load.

Clinically, mometasone furoate acts by binding to glucocorticoid receptors, reducing inflammation and edema in nasal tissues, and thereby lowering congestion and mucus production. According to reference data on mometasone from regulators and clinical studies, symptom relief tends to build over several days of consistent use, rather than delivering an instant decongestant effect. That pattern is reflected on OTC labels, which advise users to stick to daily dosing and not exceed the stated maximum sprays even if congestion persists initially.

Dosing, age limits, and cautions

Perrigo’s mometasone furoate nasal spray label specifies typical adult and adolescent dosing at two sprays into each nostril once daily, not exceeding the maximum daily dose described in the drug facts. For children younger than 12, the use is usually restricted or requires physician guidance, aligning with broader safety considerations around steroid exposure and growth in pediatric populations. The box and leaflet also warn against using the spray in the presence of untreated nasal infections or recent nasal surgery, echoing reference prescribing information for mometasone.

Users are instructed to shake the bottle gently before each use and to clean the nozzle regularly to prevent clogging, which can alter the mist pattern and dosing consistency. The drug facts further highlight potential side effects, including nasal irritation, sore throat, or nosebleeds, and recommend discontinuation and medical advice if such symptoms become pronounced or persistent. Because mometasone has relatively low systemic bioavailability at recommended doses, systemic steroid effects are rare, but the OTC label still includes general steroid warnings as a precautionary measure.

Competitive context in US allergy care

Nasonex 24HR Allergy Spray occupies a niche among OTC intranasal corticosteroids in the US, alongside generics based on fluticasone propionate, fluticasone furoate, budesonide, and triamcinolone acetonide. Market analyses published in consumer health trade media note that store-brand versions of these sprays often capture share from branded leaders by offering similar active ingredients at lower prices. Perrigo, recognized as a major supplier of OTC generics and store brands, leverages its manufacturing scale to produce multiple formulations, supplying both its own labels and retailer-branded SKUs.

In one reported investor call, Murray Kessler highlighted the company’s strength in allergy and upper respiratory categories as part of a broader self-care strategy focused on accessible treatments. Within that discussion, nasal sprays were cited as important drivers alongside oral antihistamines and cold remedies, reinforcing the role of products like Nasonex 24HR Allergy Spray in maintaining shelf presence across US pharmacies. For consumers, that translates into a familiar brand architecture: branded sprays on one shelf, store-brand equivalents immediately adjacent, with similar packaging colors and claims to make switching easier.

Manufacturing, quality, and regulatory alignment

Perrigo manufactures mometasone furoate nasal sprays under the same regulatory frameworks that govern branded prescription products, including adherence to current good manufacturing practice (cGMP) requirements. The company’s product documentation and generic drug approvals tracked in regulatory databases confirm bioequivalence and quality standards for key parameters such as spray weight, dose uniformity, and preservative content. Those metrics ensure that each activation of the pump delivers the declared amount of mometasone furoate within narrow tolerances.

A closer look at Perrigo’s allergy portfolio shows similar attention to formulation detail across intranasal products, with variations in excipient profiles to balance viscosity, spray pattern, and shelf stability. Analysts covering the OTC segment describe this capacity to manage multiple formulations as one reason retailers rely on Perrigo for house-brand allergy sprays. By aligning generic formulations closely with branded reference products in feel and performance, the company reduces friction for both pharmacists and end-users when a switch occurs at the point of sale.

Implications for US retail investors

For retail investors, Nasonex 24HR Allergy Spray is less about a single blockbuster and more about how allergy sprays collectively underpin Perrigo’s self-care franchise. The product participates in a recurring, seasonal revenue stream tied to allergic rhinitis prevalence and OTC channel dynamics in the US. Perrigo Company PLC stock (NYSE: PRGO, ISIN IE00BGH1M568) is broadly viewed by analysts as a consumer health and self-care play, with allergy products like this spray contributing to its branded and store-label portfolio.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.

de | IE00BGH1M568 | PERRIGO COMPANY PLC | boerse | 69665505 | bgmi